今海國際(02225.HK)附屬組合營 發展內窺鏡產品相關業務
今海國際(02225.HK)公布,於1月7日,全資附屬今海科技與劉鐳及俞海波組合營今海醫療,註冊資本為3,000萬元人民幣,擬通過生產、銷售及分銷(其中包括)4K、3D和熒光超高清內窺鏡產品從事提供微創手術解決方案。
公司出資1,710萬元,佔57%,並將使用未動用所得款項淨額出資。
董事會一直積極物色商機,以多元化現有業務及擴闊集團的收入基礎,從而為公司股東帶來更好回報。考慮到預期對優質醫療服務的需求將不斷增長,尤其是在新型冠狀病毒疫情期間,集團認為,成立合營公司為集團提供進入醫療解決方案行業的機會,以進一步擴大其客戶基礎及收入來源。
公司更改上市所得未動用所得款項淨額,減少部分用於增購一間外籍工人宿舍撥資,至為上述公司注入註冊資本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.